Want to see AU:RHT full AI Analyst Report?
RHT Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.07
Previous CloseN/A
Volume166.47K
Average Volume (3M)379.97K
Market Cap
AU$31.49M
Enterprise ValueAU$19.92
Total Cash (Recent Filing)AU$4.85M
Total Debt (Recent Filing)AU$3.81M
Price to Earnings (P/E)21.9
Beta1.70
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume421,255
30 Day Avg. Volume379,974
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.87
Price to Sales (P/S)1.32
P/FCF Ratio7.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ExpansionRevenue has expanded substantially over several years, indicating that Resonance Health is scaling commercial adoption of its imaging-analysis software and related services. Continued top-line growth can broaden the customer base, support operating leverage, and provide a stronger foundation for sustained profitability.
Profitability ReboundThe return to positive EBIT and net income demonstrates that the business can regain profitability after a weak period. Combined with strong gross profit, this improvement may support reinvestment in product development and commercial expansion, although continued execution is needed to prove durability.
Improved Cash GenerationPositive operating cash flow and strong free cash flow in 2026 show improved conversion of reported profitability into internally generated funds. This strengthens the company’s ability to finance operations and growth without relying as heavily on external capital, provided cash generation remains consistent.
Bears Say
Earnings VolatilityThe sharp swing between profit and loss indicates that earnings have not yet demonstrated consistent durability. Such volatility makes forward operating performance less predictable and could limit management’s ability to plan investment, allocate capital, and sustain growth through weaker periods.
Inconsistent Cash FlowThe history of negative operating and free cash flow shows that accounting profitability has not translated consistently into cash across the cycle. This weakens confidence in recurring self-funding capacity and increases the importance of maintaining recent improvements in cash conversion.
Higher Leverage Than Earlier YearsAlthough leverage is described as moderate and improved versus 2025, debt is materially higher than in 2021–2023. The larger debt burden reduces balance-sheet flexibility if profitability weakens again and may constrain future investment or increase reliance on refinancing.
Resonance Health Ltd News
RHT FAQ
What was Resonance Health Ltd’s price range in the past 12 months?
Resonance Health Ltd lowest share price was AU$0.04 and its highest was AU$0.07 in the past 12 months.
What is Resonance Health Ltd’s market cap?
Resonance Health Ltd’s market cap is AU$31.49M.
When is Resonance Health Ltd’s upcoming earnings report date?
Resonance Health Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 142 days.
How were Resonance Health Ltd’s earnings last quarter?
Resonance Health Ltd released its earnings results on Aug 27, 2026. The company reported AU$0 earnings per share for the quarter.
Is Resonance Health Ltd overvalued?
According to Wall Street analysts Resonance Health Ltd’s price is currently Overvalued.
Does Resonance Health Ltd pay dividends?
Resonance Health Ltd does not currently pay dividends.
What is Resonance Health Ltd’s EPS estimate?
Resonance Health Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resonance Health Ltd have?
Resonance Health Ltd has 477,120,240 shares outstanding.
What happened to Resonance Health Ltd’s price movement after its last earnings report?
Resonance Health Ltd reported an EPS of AU$0 in its last earnings report. Following the earnings report the stock price went down -12.308%.
Which hedge fund is a major shareholder of Resonance Health Ltd?
Currently, no hedge funds are holding shares in AU:RHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resonance Health Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHT Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$73.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Resonance Health Ltd
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Technical Analysis
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Artrya Limited
―